Dr Monk on Avutometinib Plus Defactinib in Low-Grade Serous Ovarian Cancer
June 29th 2023Bradley Monk, MD, FACS, FACOG, discusses findings from the phase 2 RAMP 201 trial in patients with low-grade serous ovarian cancer and the importance of these results within the context of the larger ovarian cancer treatment paradigm.
Advanced Ovarian Cancer: Current Treatment Landscape in Second- and Later-Line Settings
May 30th 2023Expert oncologists review the current PARP inhibitor treatment indications for patients with advanced ovarian cancer and discuss how to best manage patients who have been impacted by the recent updates to the PARP inhibitors.
The Future of Reimbursement: How AI Can Revolutionize Oncology Practices
May 15th 2023By retrospectively analyzing health care financial data and using the intelligence generated to guide future claims to a more successful outcome, machine learning platforms may reduce the need for repeated insurance submissions and appeals and can improve the practice’s clean claim rate.
Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer
March 27th 2023Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.
Acalabrutinib With or Without Obinutuzumab Maintains Long-Term Survival Benefit in Untreated CLL
Jeff P. Sharman, MD, discusses the meaning of the long-term follow-up data from ELEVATE-TN, the efficacy of acalabrutinib regimens in patients with treatment-naïve chronic lymphocytic leukemia with deletion 17p or TP53 mutations, and factors to consider when adding obinutuzumab to acalabrutinib.
Rucaparib Maintenance Shows PFS Benefit in Ovarian Cancer, Independent of HRD Status
June 6th 2022Rucaparib elicited a significant improvement in progression-free survival outcomes vs placebo as first-line maintenance therapy in patients with ovarian cancer who responded to first-line platinum-based chemotherapy across patient subgroups.
Long-Term Follow-Up Supports Acalabrutinib-Based Regimens in Treatment-Naïve CLL
June 4th 2022At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
A Widening Scope of Treatment Options Advances Care in Bladder Cancer and RCC
May 18th 2022Mark T. Fleming, MD, reviews the use of first-line checkpoint inhibitors in bladder cancer, the efficacy of enfortumab vedotin-ejfv in urothelial cancer, and the clinical benefits of using different mechanisms of action to treat renal cell carcinoma.
Patients with HER2-positive, early-stage breast cancer who achieved a pathologic complete response after receiving HER2-targeted therapy experienced better outcomes in terms of disease-free survival and overall survival vs those who did not, according to data from a real-world study.
Tisotumab Vedotin Displays Efficacy, Tolerability in Cervical Cancer
The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.
Digital Health and Process Improvements Enhance Community-Based Patient Care
October 20th 2021A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.